Bimekizumab for Plaque Psoriasis (BE CONNECTED Trial)

"This medical trial seeks to recruit 41 psoriasis sufferers between the ages of 12 and 17. Acceptable candidates will have a Psoriasis Area and Severity Index (PASI) score ≥12, body surface area affected by PSO ≥10%, Investigator's Global Assessment (IGA) score ≥3 on a 0-4 scale, Body weight ≥30 kg & BMI percentile of ≥5 at baseline. Furthermore, female participants must not be pregnant or breastfeeding and agree to contraception guidance if they are WOCBP. Informed/assent consent is also necessary from parent(s)/legal representative prior participation in this study"

"Bimekizumab was initially researched in 2018, evidenced by Ps0015 915. Since then, 26 such studies have been concluded and 8 are actively seeking enrolment. In particular, a majority of these investigations take place at Saint John's Indiana."

"The research project is no longer accepting candidates; the advert was posted on April 6th 2021 and last revised on August 19th 2022. Nevertheless, if you are still interested in enrolling for a medical trial there exist 167 clinical trials actively recruiting patients with psoriasis and 8 studies utilizing bimekizumab also seeking participants."

"At this time, enrollment for the trial is closed. The clinical study was initially published on April 6th 2021 and recently edited on August 19th 2022. If you are exploring alternative options, there are 167 trials recruiting patients with psoriasis and 8 studies searching for volunteers to participate in bimekizumab research."

"Bimekizumab has been studied since its initial clinical trial in 2018, funded by UCB Biopharma SRL. Following the success of this first study involving 743 participants, Phase 3 approval was granted and 8 additional studies are currently underway across 26 different countries with 121 sites participating."

"Our internal evaluation awarded bimekizumab a score of 2, due to the clinical data that supports its safety but not yet its efficacy."

"Currently, 12 different medical sites are running this clinical trial. These include the Saint John's location Ps0020 50359, Cypress' Ps0020 50134, and Waterloo's Ps0020 50226."

"The eligibility criteria for this trial mandates that applicants must be between 12 and 17 years of age. The database on clinicialtrials.gov hosts 32 trials specifically designed for minors, and 149 studies dedicated to individuals over 65."

"This clinical trial seeks evaluate bimekizumab Plasma concentration at Week 112 as its primary outcome. Secondary outcomes encompass the Change from Baseline in hematology parameters (erythrocytes) measured per 10^12/L, Percentage of participants with Investigator's Global Assessment (IGA) 0/1 response observed after 16 Weeks, and Change from Baseline for chemical components including calcium, potassium, sodium, blood urea nitrogen and glucose (nonfasting)."